Viatris Pulls Back to Key Support as Uptrend Remains IntactViatris, Inc.BATS:VTRSfinvestnomicsViatris (VTRS) is attracting buying interest after retracing to its 20-day moving average, a level that may provide a favorable entry point for investors. The stock remains in a constructive uptrend, characterized by a series of higher highs and higher lows while trading above its aligned 20-day and 50-day moving averages. Viatris, Inc. is a global healthcare company with a market capitalization of approximately $19.19 billion. The company develops and distributes a broad portfolio of medicines and treatments across multiple therapeutic areas, including cardiovascular disease, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. Its operations are organized into four segments: Developed Markets, Greater China, JANZ (Japan, Australia, and New Zealand), and Emerging Markets, giving the company a diversified geographic footprint across both mature and developing healthcare markets. VTRS is generally considered a no-moat company due to the highly competitive nature of the generic and off-patent pharmaceutical industry, where pricing pressure and limited product differentiation can constrain long-term competitive advantages. Nevertheless, the company has demonstrated improving operational performance, growing revenue in each of the last three quarters and improving earnings per share in two of the last three reporting periods. From a financial perspective, Viatris maintains operating and net profit margins of 10% and 5%, respectively. Return on equity (ROE) and return on invested capital (ROIC) stand at -2% and -1%, indicating that profitability and capital efficiency remain areas for improvement. The company's balance sheet remains reasonably stable, supported by a current ratio of 1.5x and a debt-to-equity ratio of 1.0x, providing adequate liquidity while maintaining a manageable debt profile.